Impact of Elevated Donor Troponin I as Predictor of Adverse Outcome in Adult Heart Transplantation: A Single-center Experience

Abstract

Background Due to globally increasing donor organ shortage, investigation of previously described risk factors for utilizing marginal donor hearts is needed. The aim of this study was to determine the impact of elevated donor serum troponin I (TnI) levels on outcome after heart transplantation (HTx).

Methods Between January 1996 and August 2013, 161 patients were reviewed for donor TnI serum levels (>0.3 ng/mL was considered elevated), postoperative outcome parameters, 30-day mortality, and 1-, 3-, and 5-year survival.

Results TnI levels were elevated in 45 (28.0%) donors. Recipients of hearts with elevated TnI had higher incidence of postoperative systolic dysfunction, prolonged inotropic support, prolonged mechanical ventilation, and longer intensive care unit (ICU) stay (p < 0.001). This group had higher 30-day mortality (22.2% vs 8.6%, p = 0.03) and lower 1-, 3-, and 5-year survival (56%, 53%, and 50% versus 82%, 76%, and 69%, p = 0.032). Elevated TnI was the only independent risk factor for 30-day mortality (odds ratio [OR] 3.63, 95% confidence interval [CI] 1.28–10.27, p = 0.015).

Conclusions Elevated donor TnI serum concentration seems to be a marker for adverse outcome and increased short- and long-term mortality after HTx. Nevertheless, many other perioperative variables and parameters can be associated with outcome.

Keywords

heart transplantation - organ donor selection - transplant outcome - troponin I

• References

• 1 Kirklin JK, Naftel DC, Kormos RL. , et al. The fourth INTERMACS annual report: 4,000 implants and counting. J Heart Lung Transplant 2012; 31 (02) 117-126
• 2 Stehlik J, Edwards LB, Kucheryavaya AY. , et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report–2011. J Heart Lung Transplant 2011; 30 (10) 1078-1094
• 3 Sheehy E, Conrad SL, Brigham LE. , et al. Estimating the number of potential organ donors in the United States. N Engl J Med 2003; 349 (07) 667-674
• 4 Wever Pinzon O, Stoddard G, Drakos SG. , et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant 2011; 11 (12) 2755-2761
• 5 Kutschmann M, Fischer-Fröhlich CL, Schmidtmann I. , et al. The joint impact of donor and recipient parameters on the outcome of heart transplantation in Germany after graft allocation. Transpl Int 2014; 27 (02) 152-161
• 6 Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36 (03) 959-969
• 7 Lin KY, Sullivan P, Salam A. , et al. Troponin I levels from donors accepted for pediatric heart transplantation do not predict recipient graft survival. J Heart Lung Transplant 2011; 30 (08) 920-927
• 8 Freundt M, Haneya A, Kolat P. , et al. Impact of cardiac troponin i as predictor of adverse outcome in heart transplantation. J Am Coll Cardiol 2015; 65 (10) A785
• 9 Fukushima N, Ono M, Saito S. , et al. Japanese strategies to maximize heart and lung availabilities: experience from 100 consecutive brain-dead donors. Transplant Proc 2013; 45 (08) 2871-2874
• 10 Weiss ES, Allen JG, Kilic A. , et al. Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantation. J Heart Lung Transplant 2012; 31 (03) 266-273
• 11 Chen JM, Sinha P, Rajasinghe HA. , et al. Do donor characteristics really matter? Short- and long-term impact of donor characteristics on recipient survival, 1995-1999. J Heart Lung Transplant 2002; 21 (05) 608-610
• 12 Lima B, Rajagopal K, Petersen RP. , et al. Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation 2006; 114 (1, Suppl) I27-I32
• 13 Ott GY, Herschberger RE, Ratkovec RR, Norman D, Hosenpud JD, Cobanoglu A. Cardiac allografts from high-risk donors: excellent clinical results. Ann Thorac Surg 1994; 57 (01) 76-81 , discussion 81–82
• 14 Tanindi A, Cemri M. Troponin elevation in conditions other than acute coronary syndromes. Vasc Health Risk Manag 2011; 7: 597-603
• 15 Wallentin L, Kristensen SD, Anderson JL. , et al. How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. Am Heart J 2014; 168 (05) 622-631
• 16 Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail 2013; 6 (02) 300-309
• 17 Riou B, Dreux S, Roche S. , et al. Circulating cardiac troponin T in potential heart transplant donors. Circulation 1995; 92 (03) 409-414
• 18 Venkateswaran RV, Ganesh JS, Thekkudan J. , et al. Donor cardiac troponin-I: a biochemical surrogate of heart function. Eur J Cardiothorac Surg 2009; 36 (02) 286-292 , discussion 292
• 19 Boccheciampe N, Audibert G, Rangeard O. , et al. Serum troponin Ic values in organ donors are related to donor myocardial dysfunction but not to graft dysfunction or rejection in the recipients. Int J Cardiol 2009; 133 (01) 80-86
• 20 Boccheciampe N, Perrier JF, Lalot JM. , et al. Sequential measurements of troponin Ic values in brain-dead patients considered as potential heart donors. Int J Cardiol 2007; 117 (01) 136-137